<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: Subscribe/RSS</title>
	<atom:link href="http://blog.pharmtech.com/subscriberss/feed/" rel="self" type="application/rss+xml" />
	<link>http://blog.pharmtech.com</link>
	<description>The blog of Pharmaceutical Technology magazine</description>
	<lastBuildDate>Thu, 09 May 2013 23:30:55 -0400</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.4</generator>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
		<item>
		<title>By: Musa Andrew Ibrahim</title>
		<link>http://blog.pharmtech.com/subscriberss/comment-page-1/#comment-2</link>
		<dc:creator>Musa Andrew Ibrahim</dc:creator>
		<pubDate>Tue, 25 Mar 2008 13:35:49 +0000</pubDate>
		<guid isPermaLink="false">http://blog.pharmtech.com/?page_id=6#comment-2</guid>
		<description>Encapsulated CD4 lymphocytes for the possible management of HIV/AIDS:
Based on the likely high affinity and specificity of CD4 -HIV virus interaction, I.V. administered semi-permeable encapsulated CD4 lymphocytes may be able to attract circulating HIV virus into the capsule and thereby effectively remove/reduce the virus from the blood of carrier patients.

Nanotechnology and biotechnology may look into this.</description>
		<content:encoded><![CDATA[<p>Encapsulated CD4 lymphocytes for the possible management of HIV/AIDS:<br />
Based on the likely high affinity and specificity of CD4 -HIV virus interaction, I.V. administered semi-permeable encapsulated CD4 lymphocytes may be able to attract circulating HIV virus into the capsule and thereby effectively remove/reduce the virus from the blood of carrier patients.</p>
<p>Nanotechnology and biotechnology may look into this.</p>
]]></content:encoded>
	</item>
</channel>
</rss>
